University of Ghent

Vib Vzw

Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw

Nestec S.a.

Alma Mater Studiorum-Universitá Di Bologna

Aarhus Universitet

Università Degli Studi Di Roma "La Sapienza"

Université Pierre Et Marie Curie (Paris Vi)

Aston University

Cranfield University

University of Konstanz

University of Innsbruck

Fundacion Centro Nacional De Investigaciones Oncologicas Carlos III

Tampereen Yliopisto

Universität Hohenheim

Claude Libert

Sebastiano Collino

Rudi Beyaert

Claudio Franceschi

Cuiying Chen

Bertrand Friguet

Roosmarijn Vandenbroucke

Filip Delaei

Sofie Van Huffel

Ben Wielockx

Eline Dejonckheere

María Moreno-Villanueva

Richard Aspinall

Martijn DollÉ

Jan H J Hoeijmakers

Ewa Sikora

Helen Griffiths

Daniela Gradinaru

Beatrix Grubeck-Loebenstein

Sofia Moco

Jürgen Bernhardt

Andreas Simm

Tilman Grune

Mercedes Gallardo

Olivier Toussaint

María Blasco

Antti Hervonen

Eugenio Mocchegiani

Marco Malavolta

Peter Kristensen

Nicolle Breusing

Alexander BÜRKLE

Paola Caiafa

Michael Berthold

Michael Junk

Efstathios S Gonos

Described are MMP8 inactivating antigen binding proteins, such as antigen binding proteins comprising an amino acid sequence that comprises 4 framework regions and 3 complementary determining regions; further described is the use of such antigen binding proteins to treat inflammation, such as, but not limited to, systemic inflammatory response syndrome, sepsis, LPS induced inflammation, renal ischemia/reperfusion injury, ventilation induced lung injury, periodontal inflammation, rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, Lyme arthritis and osteoarthritis.

MMP8 inactivating antigen binding proteins

The present invention relates to the use of the A20-binding inhibitor of NF-&#x3ba;B activation (ABIN), or a functional fragment or variant thereof to protect against TNF-induced liver failure, such as viral hepatitis and alcoholic liver disease. More particularly, it relates to the prevention of the toxic effects of said diseases, including lethality, by overexpressing ABIN.

Abin-mediated hepatitis protection

Growing community of inventors

Oudenaarde, Belgium

Claude Libert